TCV 114

Drug Profile

TCV 114

Latest Information Update: 17 Jul 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Developer David Geffen School of Medicine at UCLA; Osaka University School of Medicine; Takeda
  • Class Antihypertensives
  • Mechanism of Action Angiotensin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 17 Jul 1998 Discontinued-Clinical for Hypertension in Japan (Unknown route)
  • 17 Jul 1998 Discontinued-Clinical for Hypertension in USA (Unknown route)
  • 08 Jun 1995 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top